Insulet
(Nasdaq: PODD)
today announced positive results from a clinical trial pitting its Omnipod 5 against non-automated insulin therapy.
Acton, Massachusetts-based Insulet conducted its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 automated insulin delivery (AID) system. The company presented results at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy.
Dr. Eric Renard of Montpellier University Hospital presented the data. It highlighted Omnipod 5’s efficacy and safety compared to insulin pump therapy with CGM in adults with type 1 diabetes in the U.S. and France. The study marked the first Omnipod 5 randomized controlled trial to date. It’s also the first time the system has been evaluated by international participants.
Get the full story at our sister site, Drug Delivery Business News.